- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03277911
Thyroid Dysfunction and Dyslipidemia in Patients With Chronic Kidney Diseases
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Chronic kidney disease[CKD] is becoming a serious health problem.The number of people with impaired renal function is rapidly rising, especially in industrialized countries. It is increasing rapidly worldwide at an annual growth rate of 8%. Chronic kidney disease [CKD] is defined as kidney disease that has been present for months to years. Chronic kidney disease [CKD] is a complex disease impacting more than twenty million individuals. Progression of CKD is associated with a number of serious complications, including increased incidence of cardiovascular disease, hyperlipidemia, anemia and metabolic bone disease .CKD patients should be assessed for the presence of these complications and receive optimal treatment to reduce their morbidity and mortality .
CKD affects thyroid function in many ways, including low thyroid circulating hormone levels, altered peripheral hormone metabolism, insufficient binding to carrier proteins, reduced tissue thyroid hormone content and altered iodine storage in the thyroid gland.Thus,inCKD,thyroid hormone metabolism is impaired. . Hypothyroidism in patients with renal failure causes many metabolic and clinical problems, and both these diseases can mutually exacerbate their disturbances.. Chronic kidney disease has been known to affect thyroid hormones metabolism .Low serum level of T3 and T4 are most remarkable laboratorial finding. A high incidence of goiter and nodules on thyroid ultrasonography has been reported in patients with end stage renal failure[ESRF]. CKD is often associated with dyslipidemia. Several factors contribute to these changes. Patient with CKD have a reduction in the activity of lipoprotein lipase and hepatic triglyceride lipase. This interferes with uptake of triglyceride rich Apo lipoprotein B containing lipoprotein by the liver and in peripheral tissue, yielding increased circulation of these atherogenic lipoproteins. Early diagnosis of thyroid and lipid disorders by regular screening, and treatment of such disorders in CKD patients may be highly beneficial to slow progression of CKD.
Type d'étude
Inscription (Anticipé)
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
The study will be conducted on 80 patients with chronic kidney disease at Assuit University hospital to investigate thyroid function and lipid profile in patients with CKD of stages (1-5) and 20 subjects as a normal control. A total of newly diagnosed and known CKD cases of stage 1-5 will be included in the study.
Sample Size Calculation:
- Group I: Controls-20 age and sex matched normal individuals.
- Group II: Cases -40 patients with stage 1-3.
- Group III: Cases -40 patients with stage 4 and 5
La description
Inclusion criteria:
- Patients with CKD stage (1-5).
- Not known thyroid disorders.
- Not in lipid lowering agents.
Exclusion Criteria:
- Patients with known thyroid disorders, on medication affecting thyroid function and lipid lowering agents are excluded from the study.
- CKD patients who were or underwent previous dialysis.
- Nephrotic syndrome.
- Obesity.
- Patients on estrogens, corticosteroids, antithyroid drugs, dietary supplements.
- Pregnant woman
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
The study will be conducted to investigate thyroid function in patients with chronic kidney disease
Délai: one year
|
serum urea, creatinine, , triiodothyronine [T3], free thyroxin [T4], thyroid stimulating hormones [TSH]
|
one year
|
The study will be conducted to investigate lipid profile in patients with chronic kidney disease
Délai: one year
|
serum urea, creatinine,high density lipoprotein [HDL] cholesterol, low density cholesterol, total cholesterol, triglyceride
|
one year
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Anticipé)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Clincal Pathology
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur MRC
-
Assiut UniversityPas encore de recrutementÉlastographie, patients CKD
-
McGill University Health Centre/Research Institute...Heart and Stroke Foundation of CanadaRecrutementESRD, CKD stade 4, CKD stade 5Canada
-
St George's, University of LondonComplété
-
RWTH Aachen UniversityComplété
-
Medical University of ViennaInconnue
-
FibroGenAstraZeneca; Astellas Pharma Europe B.V.ComplétéAnémie CKD chez les patients dialysés stablesÉtats-Unis, Porto Rico
-
Menoufia UniversityTanta UniversityPas encore de recrutement
-
Seoul National University HospitalSamsung Medical Center; Pusan National University Hospital; Asan Medical Center et autres collaborateursInconnueMaladie rénale chronique (CKD)Corée, République de
-
PT. Daewoong InfionEquilab InternationalComplétéMaladie rénale chronique (CKD)Indonésie
-
University of California, San FranciscoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)ComplétéMaladie rénale chronique (CKD)États-Unis